Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Chapman PB, Gillies SD, Houghton AN, Reilly RM.

Cancer Immunol Immunother. 1994 Sep;39(3):198-204.

PMID:
7522964
[PubMed - indexed for MEDLINE]
2.

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB.

Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Review.

PMID:
9578432
[PubMed - indexed for MEDLINE]
3.

Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin.

Helling F, Livingston PO.

Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):299-309. Review.

PMID:
8086040
[PubMed - indexed for MEDLINE]
4.

Immunotherapy with monoclonal antibodies in metastatic melanoma.

Steffens TA, Bajorin DF, Houghton AN.

World J Surg. 1992 Mar-Apr;16(2):261-9. Review.

PMID:
1561808
[PubMed - indexed for MEDLINE]
5.

Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.

Wikstrand CJ, Fredman P, Svennerholm L, Bigner DD.

Prog Brain Res. 1994;101:213-23. Review.

PMID:
7518092
[PubMed - indexed for MEDLINE]
6.

Engineering antibodies for therapy.

Adair JR.

Immunol Rev. 1992 Dec;130:5-40. Review.

PMID:
1286872
[PubMed - indexed for MEDLINE]
7.

Antibody engineering.

Winter GP.

Philos Trans R Soc Lond B Biol Sci. 1989 Aug 31;324(1224):537-46; discussion 547. Review.

PMID:
2573089
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk